Use of Dopamine Agonists in Cardiovascular Medicine

  • Barry P. McGrath
  • Naoki Sano
  • Bernard F. Jover
Part of the Satellite Symposia of the IUPHAR 10th International Congress of Pharmacology book series


Intravenous DA infusion is perhaps the major pharmacological intervention in use in the management of cardiovascular disorders in Intensive Care Units. For this therapeutic advance, clinicians owe a debt of gratitude to Goldberg and his colleagues (McDonald et al., 1964; Goldberg, 1972, 1974). Yet the cardiovascular actions of DA are complex and dose-related. The effects of DA reflect the sum of many distinct and even directionally opposite cardiovascular responses to the actions of DA on a variety of different catecholamine receptors (Goldberg, 1972; Goldberg et al., 1978; Goldberg and Kohli 1979, 1983).


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ackerman, D. M., Weinstock, J., Wiebelhaus, V. D. and Berkowitz B. (1982). Renal vasodilators and hypertension. Drug. Dev. Res., 2, 283–297CrossRefGoogle Scholar
  2. Allison, N. L., Dubb, J. W., Ziemniak, J. A., Alexander, F. and Stote, R. M. (1987). The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin. Pharmac. Ther., 41, 282–288CrossRefGoogle Scholar
  3. Arnoida, L., McGrath, B. P., Cocks, M., Sumithran, E. and Johnston, C. I. (1985). Adriamycin cardiomyopathy in the rabbit: an animal model of low output cardiac failure with activation of vasoconstrictor mechanisms. Cardiovasc. Res., 19, 378–382CrossRefGoogle Scholar
  4. Baumann, G., Permanetter, B., Pfafferot, C. and Busch, U. (1986). Acute haemo-dynamic effects of dopexamine, a new positive inotropic and vasodilator substance, compared with dobutamine and sodium nitroprusside in patients with chronic myocardial insufficiency. Z. Kardiol., 75 (51), 71Google Scholar
  5. Bayliss, J., Thomas, L. and Poole-Wilson, P. (1987). Acute hemodynamic and neuroendocrine effects of dopexamine, a new vasodilator for the treatment of heart failure: comparison with dobutamine, Captopril and nitrate. J. Cardiovasc. Pharmac., 9, 551–554CrossRefGoogle Scholar
  6. Beregovich, J., Bianchi, C., Rubier, S., Lomnitz, E., Cagin, N. and Barrie, L. (1974). Dose-related hemodynamic and renal effects of dopamine in congestive heart failure. Am. Heart J., 87, 550–557PubMedCrossRefGoogle Scholar
  7. Brown, R. A., Dixon, J., Farmer, J. B., Hall, J. C., Humphries, R. G., Ince, F., O’Connor, S. E., Simpson, W. T. and Smith, G. W. (1985). Dopexamine: a novel agonist at peripheral dopamine receptors and β 2 adrenoceptors. Br. J. Clin. Pharmac., 85, 599–608CrossRefGoogle Scholar
  8. Carey, R. M., Stote, R. M., Dubb, J. W., Townsend, L. H., Rose, C. E. and Kaiser, D. L. (1984). Selective peripheral dopamine-1-receptor stimulation with fenoldopam in human essential hypertension. J. Clin. Invest., 74, 2198–2207PubMedPubMedCentralCrossRefGoogle Scholar
  9. Cavero, I., Massingham, R. and Lefevre-Borg, F. (1982). Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part I: subclassification and functional description. Life Sci., 31, 939–948PubMedCrossRefGoogle Scholar
  10. CONSENSUS Trial Study Group (1987). Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl. J. Med., 316, 1429–1435CrossRefGoogle Scholar
  11. Dawson, J. R., Thompson, D. S., Signy, M., Juul, S. M., Turnbull, P., Jenkins, B. S. and Webb-Peploe, M. M. (1985). Acute haemodynamic and metabolic effects of dopexamine, a new dopaminergic receptor agonist, in patients with chronic heart failure. Br. Heart J., 54, 313–320PubMedPubMedCentralCrossRefGoogle Scholar
  12. Dei Cas, L., Bolognesi, R., Cucchini, F., Fappani, A., Riva, S. and Visioli, O. (1983). Hemodynamic effects of ibopamine in patients with idiopathic congestive cardiomyopathy. J. Cardiovasc. Pharmac., 5, 239–253CrossRefGoogle Scholar
  13. Fennell, W. H., Taylor, A. A., Young, J. B., Brandon, T. A., Ginos, J. Z., Goldberg, L. I. and Mitchell, J. R. (1983). Propylbutyldopamine: hemodynamic effects in conscious dogs, normal human volunteers and patients with heart failure. Circulation, 67, 829–836PubMedCrossRefGoogle Scholar
  14. Francis, G. S., Parks, R. and Cohn, J. N. (1983). The effects of bromocriptine in patients with congestive heart failure. Am. Heart J., 106, 100PubMedCrossRefGoogle Scholar
  15. Glück, Z., Jossen, L., Weidmann, P., Guädinger, M. P. and Peheim, E. (1987). Cardiovascular and renal profile of acute peripheral dopamine-1-receptor agonism with fenoldopam. Hypertension, 10, 43–54PubMedCrossRefGoogle Scholar
  16. Goldberg, L. I. (1972). Cardiovascular and renal actions of dopamine. Potential clinical applications. Pharmac. Rev., 24, 1–24Google Scholar
  17. Goldberg, L. I. (1974). Dopamine: clinical uses of an endogenous catecholamine. New Engl. J. Med., 291, 707–710PubMedCrossRefGoogle Scholar
  18. Goldberg, L. I., Hsieh, Y. Y. and Resnekov, L. (1977). Newer catecholamines for the treatment of heart failure and shock: An update on dopamine and a first look at dobutamine. Prog. Cardiovasc. Dis., 19, 327–340PubMedCrossRefGoogle Scholar
  19. Goldberg, L. I. and Kohli, J. D. (1979). Peripheral pre- and post-synaptic dopamine receptors: Are they different from dopamine receptors in the central nervous system? Commun. Psychopharmac., 3, 447–456Google Scholar
  20. Goldberg, L. I. and Kohli, J. D. (1983). In Kaiser, C. and Kebabian J. W. (Eds.), Dopamine Receptors, Maple Press, York, Pennsylvania, pp. 101–113CrossRefGoogle Scholar
  21. Goldberg, L. I., Volkman, P. H. and Kohli, J. D. (1978). A comparison of the vascular dopamine receptor with other dopamine receptors. Ann. Rev. Pharmac. Toxicol., 18, 57–79CrossRefGoogle Scholar
  22. Hahn, R. A. and McDonald, B. R. (1984). Systemic hemodynamic and regional blood flow effects of LY141865, a selective dopamine receptor agonist. J. Pharmac. Exp. Ther., 230, 538–568Google Scholar
  23. Hahn, R. A., Wardell, J. R., Sarau, H. M. and Ridley, P. T. (1982). Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J. Pharmac. Exp. Ther., 223, 305–314Google Scholar
  24. Harvey, J. N., Worth, D. P., Brown, J. and Lee, M. R. (1985). The effects of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man. Br. J. Clin. Pharmac., 19, 21–27CrossRefGoogle Scholar
  25. Harvey, J. N., Worth, D. P., Brown, J. and Lee, M. R. (1986). Studies with fenoldopam, a dopamine receptor DA-1 agonist, in essential hypertension. Br. J. Clin. Pharmac., 21, 53–61CrossRefGoogle Scholar
  26. Jaski, B. E., Wijns, W., Foulds, R. and Serruys, P. W. (1986). The haemodynamic and myocardial effects of dopexamine: a new β 2-adrenoceptor and dopamine agonist. Br. J. Clin. Pharmac., 21, 393–400CrossRefGoogle Scholar
  27. Jover, B., McGrath, B. and Trigg, L. (1988). Beneficial effects of fenoldopam on systemic and regional hemodynamics in rabbits with congestive heart failure. J. Cardiovasc. Pharmac., 11, 483–488CrossRefGoogle Scholar
  28. Lipkin, D. P. and Poole-Wilson, P. A. (1985). Treatment of chronic heart failure: a review of recent drug trials. Br. Med. J., 291, 993–996CrossRefGoogle Scholar
  29. McDonald, R. H., Goldberg, L. I., McNay, J. L. and Tuttle, E. P. Jr. (1964). Effects of dopamine in man: augmentation of sodium excretion, glomerular filtration rate and renal plasma flow. J. Clin. Invest., 43, 1116–1124PubMedPubMedCentralCrossRefGoogle Scholar
  30. McGrath, B. P., Arnolda, L., Matthews, P. G., Jackson, B., Jennings, G., Kiat, H. and Johnston, C. I. (1985). Controlled trial of enalapril in congestive heart failure. Br. Heart J., 54, 405–414PubMedPubMedCentralCrossRefGoogle Scholar
  31. McGrath, B. P., Jover, B. F., Trigg, L. and Arnolda, L. F. (1987). Adriamycin-induced cardiomyopathic heart failure in the rabbit. In Kawai, C. and Abelmann, W. (Eds.), Pathogenesis of Myocarditis and Cardiomyopathy. Recent experimental and clinical studies, University of Tokyo Press, Tokyo, pp. 121–133Google Scholar
  32. Maskin, C. S., Ocken, S., Chadwick, B. and LeJemtel, T. H. (1985). Comparative systemic and renal effects of dopamine and angiotensin converting enzyme inhibition with enalaprilat in patients with heart failure. Circulation, 72, 846–852PubMedCrossRefGoogle Scholar
  33. Merrill, A. J. (1945). Edema and decreased renal blood flow in patients with chronic congestive heart failure: Evidence of ‘forward failure’ as the primary cause of edema. J. Clin. Invest., 49, 389–400Google Scholar
  34. Ohlstein, E. H., Zabko-Potapovich, B. and Berkowitz, B. A. (1985). The DA1 receptor agonist fenoldopam (SK&F 82526) is also an α-adrenoceptor antagonist. Eur. J. Pharmac., 118, 321–329CrossRefGoogle Scholar
  35. Rajfer, S. I., Anton, A. H., Rossen, J. D. and Goldberg, L. I. (1984). Beneficial hemodynamic effects of oral levodopa in heart failure. New Engl. J. Med., 310, 1357–1362PubMedCrossRefGoogle Scholar
  36. Rajfer, S. I. and Goldberg, L. I. (1983). Dopamine in the treatment of heart failure. Eur. Heart J., 3, 103–106Google Scholar
  37. Ren, J. H., Unverferth, D. V. and Leier, C. V. (1984). The dopamine congener, ibopamine, in congestive heart failure. J. Cardiovasc. Pharmac., 6, 748–755CrossRefGoogle Scholar
  38. Stote, R. M., Dubb, J. W., Familiar, R. G., Erb, B. B. and Alexander, F. (1983). A new oral renal vasodilator, fenoldopam. Clin. Pharmac. Ther., 34, 209–215CrossRefGoogle Scholar
  39. Stumpe, K. O., Kolloch, R., Higuchi, M., Kruch, F. and Vetter, H. (1977). Hyperpro-lactinaemia and antihypertensive effect of bromocriptine in essential hypertension: Identification of abnormal central dopamine control. Lancet, ii, 211–214CrossRefGoogle Scholar
  40. Svensson, G., Sjögren, A. and Erhardt, L. (1986). Short-term haemodynamic effects of dopexamine in patients with chronic congestive heart failure. Eur. Heart J., 7, 697–703PubMedGoogle Scholar
  41. Ventura, H. O., Messerli, F. H., Frolich, E. D., Kobrin, I., Oigman, W., Dunn, F. G. and Carey, R. M. (1984). Immediate hemodynamic effect of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension: Circulation, 69, 1142–1145PubMedCrossRefGoogle Scholar
  42. Wanless, R. B., Anand, C. S., Poole-Wilson, P. A. and Harris, P. (1987). An experimental model of chronic cardiac failure using adriamycin in the rabbit: central haemodynamics and regional blood flow. Cardiovasc. Res., 21, 7–13PubMedCrossRefGoogle Scholar
  43. Young, J. B., Leon, C. A., Pratt, C. M., Suarez, J. M., Aronoff, R. D. and Roberts, R. (1985). Haemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure. J. Am. Coll. Cardiol., 6, 792–796PubMedCrossRefGoogle Scholar
  44. Zelis, R. and Flaim, S. F. (1982). Alterations in vasomotor tone in congestive heart failure. Prog. Cardiovasc. Dis., 24, 437–459PubMedCrossRefGoogle Scholar

Copyright information

© Barry P. McGrath, Naoki Sano and Bernard F. Jover 1988

Authors and Affiliations

  • Barry P. McGrath
  • Naoki Sano
  • Bernard F. Jover

There are no affiliations available

Personalised recommendations